Unipathic Medicine in Cancer Treatment Moving Forward

Unipathic Medicine is greatly advancing in the way doctors approach cancer treatment. Genetically Targeted Fractionated Chemotherapy (GTFC) and immunotherapy are just two examples. In particular and for the sake of this article, we have known the potential immunotherapy has for prolonging or saving life in patients for some time now, and that is why we are excited by the news that combination immunotherapy is starting to take off and is helping patients. Unipathic Medicine itself has been accomplishing this for quite some time now. It is good news for pancreatic cancer sufferers, that there is a new breakthrough cancer treatment in the works. As presented by Fox News, “According to study results, patients who received the combination of GVAX Pancreas and CRS-207 cancer vaccines had better outcomes than those who received GVAX Pancreas vaccine alone.” And that’s not all: “Experts are hopeful that combination immunotherapy could help extend the lives of those with metastatic pancreatic cancer” (1). This particular vaccine works when is the immune system is triggered to target the cancer tumor, and the result is a patient’s life is prolonged by 2 to 3 months. The medical community must improve…but this is a step in the right direction. Unipathic Medicine promotes the highest levels of personalized immunotherapy and our approach to cancer involves genetic profiling, molecular profiling, and detailed immunotherapy many times in conjunction. Our stance is strongly immune centered and we use a genetically targeted fractionated form of chemotherapy which is micro dose, and immune friendly, and enhancing in many cases.

There is clearly a demand and need for new therapies, and Unipathic Medicine is on the front lines getting this done with the latest technologies from all over the world. Here is a stunning fact, “The FDA had received 170 breakthrough therapy requests from companies from the start of the program in July 2012 through July 11 of this year; 88 of those requests had been denied.” That’s about a 50 percent success rate! We know just how hard it is to get clinical drug trials passed. Even though the FDA is just doing its job to help with public safety, there are already many wonderful options that exist and they involve a higher level of testing and customization for each patient.

Our ultimate goal is for Unipathic Medicine to become more available to physicians and patients. Targeted, integrated medicine is showing great promise and along with the ever evolving targeted treatments that we have, such as GTFC, AAIT, and others being developed such as CRS-207 and GVAX pancreas; finally patients can achieve the personalization they have been seeking. If you wish to learn more about Unipathic Medicine, please contact us.

References

[1] Samadi, David B. “New pancreatic cancer therapy labeled ‘breakthrough’ by FDA.” Fox News. July 29, 2014. http://www.foxnews.com/health/2014/07/29/new-pancreatic-cancer-therapy-labeled-breakthrough-by-fda/

[2] Leuty, Ron. “Pancreatic cancer treatment that almost never was lands key FDA win.” San Francisco Business Times. July 21, 2014. http://www.bizjournals.com/sanfrancisco/blog/biotech/2014/07/pancreatic-cancer-aduro-gvax-steve-jobs.html?page=all